المؤلفون: van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.vandeloosdrecht@amsterdamumc.nl., Cremers EMP; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Alhan C; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Duetz C; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., In 't Hout FEM; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Visser-Wisselaar HA; HOVON Foundation, Rotterdam, The Netherlands., Chitu DA; HOVON Foundation, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Verbrugge A; HOVON Foundation, Rotterdam, The Netherlands., Cunha SM; HOVON Foundation, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Janssen JJWM; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Klein SK; Department of Hematology, Meander Medisch Centrum, Amersfoort, The Netherlands.; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Vellenga E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Huls GA; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Muus P; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Haematology, St. James University Hospital, Leeds, UK., Langemeijer SMC; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., de Greef GE; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Te Boekhorst PAW; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Raaijmakers MHG; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Marwijk Kooy M; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands., Legdeur MC; Department of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands., Wegman JJ; Department of Hematology, Deventer Ziekenhuis, Deventer, The Netherlands.; Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands., Deenik W; Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, The Netherlands.; Department of Internal Medicine, Rijnstate, Arnhem, the Netherlands., de Weerdt O; Department of Internal Medicine, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands., van Maanen-Lamme TM; Department of Internal Medicine, Dijklander Ziekenhuis, Hoorn, The Netherlands., Jobse P; Department of Internal Medicine, Admiraal de Ruyter Ziekenhuis, Goes, The Netherlands., van Kampen RJW; Department of Internal Medicine, Zuyderland Ziekenhuis, Geleen, The Netherlands., Beeker A; Department of Hematology, Spaarne Gasthuis, Hoofddorp, The Netherlands., Wijermans PW; Department of Hematology, Haaglanden Ziekenhuis, Den Haag, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands., Tanis BC; Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands.; Department of General Practice Erasmus MC, Rotterdam, The Netherlands., van Esser JWJ; Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands., Schaar CG; Department of Internal Medicine, Gelre Ziekenhuis, Apeldoorn, The Netherlands., Noordzij-Nooteboom HS; Department of Internal Medicine, Van Weel Bethesda Ziekenhuis, Dirksland, The Netherlands., Jacobs EMG; Department of Internal Medicine, Elkerliek Ziekenhuis, Helmond, The Netherlands., de Graaf AO; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Stevens-Kroef MJPL; Department of human genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Westers TM; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Jansen JH; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

المصدر: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 840-850. Date of Electronic Publication: 2024 Jan 31.

نوع المنشور: Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Hematinics*/pharmacology , Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/genetics, Humans ; Lenalidomide/pharmacology ; Erythropoiesis ; Granulocyte Colony-Stimulating Factor/pharmacology ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Treatment Outcome

المؤلفون: Chamuleau MED; Department of Hematology, Amsterdam University Medical Center, Location VU, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands. Electronic address: m.chamuleau@amsterdamumc.nl., Stenner F; Department of Oncology, University Hospital Basel, University of Basel, Basel, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Chitu DA; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Novak U; Department of Medical Oncology, Inselspital /Bern University Hospital, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Minnema MC; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Geerts P; Department of Hematology, Isala Clinics, Zwolle, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Stevens WBC; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Zenz T; Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., van Imhoff GW; Department of Hematology, University Medical Center Groningen, Groningen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Wu KL; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Stuivenberg, Antwerp, Belgium; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Demandt AMP; Division of Hematology, Department of Internal Medicine, School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Kersten MJ; Department of Hematology, Amsterdam University Medical Center, location University of Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Terpstra WE; Department of Hematology, Amsterdam-Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Tick LW; Department of Internal Medicine, Máxima Medical Center, Eindhoven, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Deeren D; Department of Hematology, Algemeen Ziekenhuis Delta, Roeselare, Belgium; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Van Den Neste E; Department of Hematology, Cliniques universitaires Université catholique de Louvain Saint-Luc, Belgium., Gregor M; Department of Hematology, Luzerner Kantonsspital, Luzern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Veelken H; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Böhmer LH; Department of Hematology Haga Teaching Hospital, The Hague, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Caspar CB; Department of Internal Medicine, Division of Medical Oncology and Hematology, Kantonsspital Baden, Baden, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Mutsaers P; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Refos JM; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Sewsaran R; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Fu L; Pathology Facility, Amsterdam University Medical Center, Location VU, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Seefat RL; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Uyl-de Groot CA; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Netherlands., Dirnhofer S; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Van Den Brand M; Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., de Jong D; Department of Pathology, Amsterdam University Medical Center, Location VU, Amsterdam, Netherlands; Cancer Centre Amsterdam, Amsterdam, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Nijland M; Department of Hematology, University Medical Center Groningen, Groningen, Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Amsterdam, Netherlands., Lugtenburg P; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

المصدر: The Lancet. Haematology [Lancet Haematol] 2023 Dec; Vol. 10 (12), pp. e966-e975. Date of Electronic Publication: 2023 Oct 31.

نوع المنشور: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Burkitt Lymphoma*/diagnosis , Burkitt Lymphoma*/drug therapy, Humans ; Male ; Female ; Etoposide ; Vincristine ; Rituximab/therapeutic use ; Methotrexate ; Cytarabine ; Cyclophosphamide/adverse effects ; Doxorubicin ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Prednisolone/therapeutic use

SCR Protocol: EPOCH protocol

المؤلفون: Hilberink JR; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., van Zeventer IA; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Pabst T; Department of Oncology, University Hospital, Inselspital, and University of Bern, Bern, Switzerland., Klein SK; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.; Department of Internal Medicine, Meander Hospital Amersfoort, Amersfoort, the Netherlands., Stussi G; Department of Hematology, Oncology Institute of Southern Switzerland, Ospedale Regionale, Bellinzona, Switzerland., Griskevicius L; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania., Valk PJM; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Breems D; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium., van Lammeren-Venema D; Department of Hematology, Hagaziekenhuis, Den Haag, the Netherlands., Boersma R; Department of Hematology, Amphia Hospital, Breda, the Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Fehr M; Department of Medical oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Manz MG; Department of Medical Oncology and Hematology, Universitätsspital Zurich, Zurich, Switzerland., Söhne M; Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands., van Marwijk Kooy R; Department of Hematology, Isala Hospital, Zwolle, the Netherlands., Deeren D; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium., van der Poel MWM; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Legdeur MC; Department of Hematology, Medical Spectrum Twente, Enschede, the Netherlands., Tick L; Department of hematology, Maxima Medical Center, Veldhoven, the Netherlands., Chalandon Y; Division of hematology, University Hospital Genève and Faculty of Medicine, University of Genève, Genève, Switzerland., Ammatuna E; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Blum S; Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Löwenberg B; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Huls G; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands. g.huls@umcg.nl.

مؤلفون مشاركون: Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

المصدر: Blood cancer journal [Blood Cancer J] 2023 Jun 19; Vol. 13 (1), pp. 93. Date of Electronic Publication: 2023 Jun 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Myelodysplastic Syndromes*/genetics , Leukemia, Myeloid, Acute*/genetics, Humans ; Male ; Female ; Aged ; Decitabine/therapeutic use ; Mutation ; Treatment Outcome

المؤلفون: Westers TM; Department of Hematology, Amsterdam University Medical Centers, Location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Alhan C; Department of Hematology, Amsterdam University Medical Centers, Location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Visser-Wisselaar HA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam University Medical Centers, Location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

المصدر: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2023 Mar; Vol. 104 (2), pp. 162-172. Date of Electronic Publication: 2021 Nov 22.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 101235690 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4957 (Electronic) Linking ISSN: 15524949 NLM ISO Abbreviation: Cytometry B Clin Cytom Subsets: MEDLINE

مواضيع طبية MeSH: Hemoglobinuria, Paroxysmal*/diagnosis , Hemoglobinuria, Paroxysmal*/metabolism , Myelodysplastic Syndromes*/diagnosis , Myelodysplastic Syndromes*/metabolism , Anemia, Aplastic*/diagnosis, Humans ; Bone Marrow/metabolism ; Prospective Studies ; Flow Cytometry/methods

المؤلفون: van Grootveld R; Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. r.van_grootveld@lumc.nl., Masarotto V; Mathematical Institute, Leiden University, Leiden, The Netherlands., von dem Borne PA; Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands., Blijlevens NMA; Department of Haematology, Radboud University Medical Center, Nijmegen, The Netherlands., Chitu DA; Department of Haematology, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Beek MT; Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands., Fiocco M; Mathematical Institute, Leiden University, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., de Boer MGJ; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.

المصدر: BMC infectious diseases [BMC Infect Dis] 2023 Feb 06; Vol. 23 (1), pp. 78. Date of Electronic Publication: 2023 Feb 06.

نوع المنشور: Randomized Controlled Trial; Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/complications , Leukemia, Myeloid, Acute*/drug therapy , Aspergillosis*/complications , Invasive Fungal Infections*/complications , Myelodysplastic Syndromes*/complications, Adult ; Humans ; Male ; Aged ; Female ; Cause of Death

المؤلفون: Duetz C; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands., Westers TM; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands., In 't Hout FEM; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands., Cremers EMP; Department of Hematology, Maastricht University Medical Center, Maastricht, the Netherlands., Alhan C; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands., Venniker-Punt B; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands., Visser-Wisselaar HA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., de Graaf AO; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands., Smit L; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands., Jansen JH; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands., van de Loosdrecht AA; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.

المصدر: British journal of haematology [Br J Haematol] 2021 May; Vol. 193 (4), pp. 798-803. Date of Electronic Publication: 2021 Mar 25.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Chromosomes, Human, Pair 5*/genetics , Chromosomes, Human, Pair 5*/immunology , Gene Deletion* , Immunophenotyping* , Myelodysplastic Syndromes*/classification , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/immunology , Phosphoproteins*/genetics , Phosphoproteins*/immunology , RNA Splicing Factors*/genetics , RNA Splicing Factors*/immunology, Bone Marrow Cells/*immunology, Female ; Humans ; Male

المؤلفون: Huls G; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Pabst T; Department of Oncology, University Hospital, Inselspital, and University of Bern, Bern, Switzerland., Klein SK; Department of Hematology, Meander Hospital Amersfoort, Amersfoort, The Netherlands., Stussi G; Department of Hematology, Ospedale Regionale, Bellinzona, Switzerland., Griskevicius L; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania., Valk PJM; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Breems D; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium., van Lammeren-Venema D; Department of Hematology, Hagaziekenhuis, Den Haag, The Netherlands., van Zeventer I; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Boersma R; Department of Hematology, Amphia Hospital, Breda, The Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Fehr M; Department of Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Manz MG; Department of Medical Oncology and Hematology, Universitätsspital Zurich, Zurich, Switzerland., Söhne M; Department of Hematology, Antonius Hospital, Nieuwegein, The Netherlands., van Marwijk Kooy R; Department of Hematology, Isala Hospital, Zwolle, The Netherlands., Deeren D; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium., van der Poel MWM; Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands., Legdeur MC; Department of Hematology, Medical Spectrum Twente, Enschede, The Netherlands., Tick L; Department of Hematology, Maxima Medical Center, Veldhoven, The Netherlands., Chalandon Y; Division of Hematology, University Hospital Genève and Faculty of Medicine, University of Genève, Genève, Switzerland; and., Ammatuna E; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Blum S; Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Löwenberg B; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

المصدر: Blood advances [Blood Adv] 2020 Sep 22; Vol. 4 (18), pp. 4267-4277.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Myelodysplastic Syndromes*, Adenine/analogs & derivatives ; Decitabine/therapeutic use ; Humans ; Netherlands ; Piperidines

المؤلفون: Doorduijn JK; Haematology, Erasmus MC Cancer Centre, Rotterdam, Netherlands., Zijlstra JM; Amsterdam UMC - Locatie VUMC, Amsterdam, Netherlands., Lugtenburg PJ; Erasmus MC Cancer Centre, Rotterdam, Netherlands., Kersten MJ; Haematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (lymphoma and myeloma Center), Amsterdam, Netherlands., Böhmer LH; Haematology, Haga Teaching Hospital, The Hague, USA., Minnema MC; Haematology, UMC Utrecht Cancer Centre, Utrecht, Netherlands., MacKenzie MA; UMCN, Nijmegen, Netherlands., van Marwijk Kooij R; Internal Medicine, Isala Clinic, Zwolle, Netherlands., de Jongh E; Albert Schweitzer Hospital Location Dordwijk, Dordrecht, Netherlands., Snijders TJF; Medisch Spectrum Twente, Enschede, Netherlands., de Weerdt O; Sint Antonius Hospital, Nieuwegein, Netherlands., van Gelder M; Maastricht University Medical Centre+, Maastricht, Netherlands., Hoogendoorn M; Medical Centre Leeuwarden, Leeuwarden, Netherlands., Leys RBL; Maasstad Ziekenhuis, Rotterdam, Netherlands., Kibbelaar RE; Department of Pathology, Pathology Friesland, Groningen, Netherlands., de Jong D; Amsterdam UMC - Locatie VUMC, Amsterdam, Netherlands., Chitu DA; Erasmus MC Cancer Center, Rotterdam, Netherlands., Van't Veer MB; Erasmus MC Cancer Centre, Rotterdam, Netherlands., Kluin-Nelemans HC; Haematology, University Medical Center Groningen, Groningen, Netherlands.

المصدر: British journal of haematology [Br J Haematol] 2020 Aug; Vol. 190 (3), pp. 385-393. Date of Electronic Publication: 2020 Mar 09.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bortezomib/*therapeutic use , Lymphoma, Mantle-Cell/*drug therapy, Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Carmustine/administration & dosage ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Mantle-Cell/therapy ; Male ; Melphalan/administration & dosage ; Middle Aged ; Netherlands ; Prednisone/administration & dosage ; Progression-Free Survival ; Remission Induction ; Rituximab/administration & dosage ; Transplantation, Autologous ; Treatment Failure ; Vincristine/administration & dosage ; Young Adult

SCR Protocol: BEAM regimen; CHOP protocol

المؤلفون: Huls G; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Havelange V; Department of Hematology, Cliniques Universitaires St. Luc, Brussels, Belgium., Jongen-Lavrencic M; Department of Hematology, Erasmus MC, Rotterdam, The Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam University Medical Center, Academic Medical Center Amsterdam, Amsterdam, The Netherlands., Sinnige H; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Hodossy B; Department of Hematology, Citadelle, Liege, Belgium., Graux C; Department of Hematology, Université Catholique de Louvain, University Medical Center Catholic University of Leuven Namur, Yvoir, Belgium., Kooy RVM; Department of Hematology, Isala Hospital, Zwolle, The Netherlands., de Weerdt O; Department of Hematology, Antonius Hospital, Nieuwegein, The Netherlands., Breems D; Department of Hematology, Hospital Network Antwerp (ZNA) Stuivenberg/Middelheim, Antwerp, Belgium., Klein S; Department of Hematology, Meander Hospital Amersfoort, Amersfoort, The Netherlands., Kuball J; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands., Deeren D; Department of Hematology, General Hospital Delta Roeselare, Roeselare, Belgium; and., Terpstra W; Department of Hematology, Our Dear Lady Hospital (OLVG), Amsterdam, The Netherlands., Vekemans MC; Department of Hematology, Cliniques Universitaires St. Luc, Brussels, Belgium., Ossenkoppele GJ; Department of Hematology, Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Vellenga E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Löwenberg B; Department of Hematology, Erasmus MC, Rotterdam, The Netherlands.

مؤلفون مشاركون: Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

المصدر: Blood [Blood] 2019 Mar 28; Vol. 133 (13), pp. 1457-1464. Date of Electronic Publication: 2019 Jan 10.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Antimetabolites, Antineoplastic/*therapeutic use , Azacitidine/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy, Age Factors ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/epidemiology ; Maintenance Chemotherapy ; Male ; Middle Aged ; Remission Induction

المؤلفون: van Eijkelenburg NKA; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France., Rasche M; Department of Pediatric Oncology, University Children's Hospital, Essen, Germany., Ghazaly E; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK., Dworzak MN; Children's Cancer Research Institute and St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, Austria., Klingebiel T; Pediatric Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany., Rossig C; Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany., Leverger G; Department of Pediatric Hematology and Oncology, AP-HP, GH HUEP, Trousseau Hospital, Paris, France., Stary J; Department of Pediatric Hematology and Oncology, 2Faculty of Medicine, Charles University Prague, University Hospital Motol, Czech Republic., De Bont ESJM; Department of Pediatric Oncology, University Medical Center Groningen, University of Groningen, the Netherlands., Chitu DA; Clinical Trial Center, Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands., Bertrand Y; Pediatric Hematology Department, IHOP and Claude Bernard University, Lyon, France., Brethon B; Department of Pediatric Hematology, Robert Debré Hospital, Paris, France., Strahm B; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Germany., van der Sluis IM; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France., Kaspers GJL; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands.; I-BFM-AML committee, Kiel, Germany., Reinhardt D; European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France.; I-BFM-AML committee, Kiel, Germany., Zwaan CM; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands c.m.zwaan@erasmusmc.nl.; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; European Consortium for Innovative Therapies for Children with Cancer (ITCC), Villejuif, France.

المصدر: Haematologica [Haematologica] 2018 Sep; Vol. 103 (9), pp. 1484-1492. Date of Electronic Publication: 2018 May 17.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy, Adolescent ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Child ; Child, Preschool ; Clofarabine/administration & dosage ; Clofarabine/pharmacokinetics ; Cytarabine/administration & dosage ; Cytarabine/pharmacokinetics ; Daunorubicin/administration & dosage ; Daunorubicin/pharmacokinetics ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Humans ; Infant ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Liposomes ; Male ; Recurrence ; Remission Induction ; Retreatment ; Survival Analysis ; Treatment Outcome ; Young Adult